Glaukos (NYSE:GKOS) Upgraded by Mizuho to Outperform Rating

Glaukos (NYSE:GKOS) was upgraded by equities researchers at Mizuho from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The brokerage currently has a $200.00 target price on the medical instruments supplier’s stock, up from their prior target price of $140.00. Mizuho’s price objective indicates a potential upside of 30.72% from the stock’s current price.

Several other research analysts have also recently commented on the company. Wells Fargo & Company boosted their price target on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Truist Financial upped their price objective on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $159.42.

Glaukos Price Performance

Shares of NYSE GKOS opened at $153.00 on Wednesday. Glaukos has a 1-year low of $83.90 and a 1-year high of $163.71. The business has a 50-day moving average of $151.95 and a 200-day moving average of $138.62. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of -50.66 and a beta of 1.04.

Insider Activity

In related news, COO Joseph E. Gilliam sold 3,328 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Glaukos

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming grew its holdings in Glaukos by 2.3% during the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 72 shares during the period. Quadrant Capital Group LLC raised its position in shares of Glaukos by 3.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock valued at $345,000 after buying an additional 73 shares in the last quarter. Mutual of America Capital Management LLC raised its position in Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after purchasing an additional 89 shares in the last quarter. HighTower Advisors LLC raised its position in Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after purchasing an additional 91 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its position in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.